כל המחקרים
גיוסאישור טיפולי (שלב III)התערבותי

The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

ENPP1 deficiency is a very rare genetic condition where the body cannot make enough of an essential enzyme. This leads to low levels of a substance called pyrophosphate, causing problems with bone strength, rickets, and calcium build-up in blood vessels. The ENERGY 3 trial is a Phase 3 study looking at a new treatment called INZ-701 in children with this condition. The main aim is to find out if INZ-701 can restore healthy mineral levels in the blood and help heal bone problems caused by rickets. Doctors will measure bone changes using X-rays and track each child's height, weight, and general health over 52 weeks. Taking part helps researchers understand if this treatment is safe and effective for long-term use.

במבט חטוף

סטטוס
גיוס
שלב
אישור טיפולי (שלב III)
נותן חסות
Inozyme Pharma Inc.
יעד הרשמה
8
התחל
06 Mar 2024

על מה המחקר הזה?

ENPP1 deficiency is a rare inherited condition that affects how the body manages minerals like calcium and phosphate. In healthy bodies, an enzyme called ENPP1 produces a protective substance called pyrophosphate, which stops calcium from building up where it should not, while keeping bones strong. Children with this condition often experience weakened bones, rickets, and problems in their blood vessels.

INZ-701 is an experimental medicine designed to act as an enzyme replacement. By providing the missing enzyme activity, it aims to boost levels of pyrophosphate in the blood. If successful, this could help prevent abnormal calcium deposits, support normal bone development, and relieve symptoms related to bone weakness.

The ENERGY 3 study is a Phase 3 clinical trial, which means it is an advanced stage of testing. Researchers want to confirm how well INZ-701 works and check its safety in children. Over 52 weeks (one year), the study team will closely monitor whether the medicine improves rickets on X-rays, aids normal physical growth, and keeps children safe from unwanted side effects.

נקודות עיקריות

  • ENERGY 3 is testing INZ-701, an experimental medicine for children with ENPP1 deficiency.
  • The treatment aims to restore healthy mineral levels and heal bone problems like rickets.
  • Children will be monitored closely for 52 weeks with blood tests, X-rays, and growth checks.
  • Participation is entirely voluntary, and families can withdraw at any point.

מי עשוי להיות זכאי?

This trial is specifically for children who have been diagnosed with ENPP1 deficiency. It is open to both boys and girls. Because this is a specialist study for a rare condition, a doctor will need to confirm the diagnosis through genetic testing and clinical checks.

Children will need to be well enough to attend regular hospital check-ups and complete tests such as blood draws and imaging scans.

Not every child with the condition will be able to join. Factors such as other serious medical conditions, recent use of certain medications, or specific allergies may mean a child cannot safely take part. The study doctor can review these details with families.

האם מחקר זה יכול להתאים לך?

ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.

  1. My child has a confirmed diagnosis of ENPP1 deficiency.
  2. My child is a child or young person suitable for paediatric study monitoring.
  3. We are able to attend regular hospital appointments over a 52-week period.
  4. We are willing for our child to have regular blood tests, growth checks, and bone X-rays.
ענה על כל שאלה כדי לראות את התוצאה שלך.

מה כרוך בהשתתפות?

Taking part in the ENERGY 3 study lasts for around 52 weeks (one year). During this time, children will receive the study medicine, INZ-701, and attend regular appointments at a specialist hospital clinic. At these visits, the medical team will carry out physical examinations, check vital signs, and measure height and weight to track growth. Children will have regular blood tests to check levels of pyrophosphate and monitor how the medicine is working in the body. The team will also take X-rays to assess bone healing and look for any signs of rickets. Parents and carers will be supported by the study team throughout, with regular follow-up checks to monitor health and wellbeing.

סיכונים ותועלות פוטנציאליים

Joining the study may offer the potential benefit of improving your child's bone health, mineral balance, and physical growth, although benefits cannot be guaranteed. There are also risks to consider. As with any new medicine, INZ-701 may cause unexpected side effects or reactions around the injection site, and study tests like blood samples can cause mild discomfort. Taking part is completely voluntary. You are free to withdraw your child from the study at any time without giving a reason, and this will never affect their standard NHS care.

מיקומים (2)

חלק מהמיקומים באתר הם משוערים. אנחנו עובדים על שיפור זה — אנא ודאו עם צוות הניסוי לפני הנסיעה.
  • —
    לא מאומת
    צרפת
  • —
    לא מאומת
    ספרד

שאלות נפוצות

What is ENPP1 deficiency?

It is a rare genetic condition where the body lacks an important enzyme, leading to weak bones, rickets, and calcium deposits in tissues.

What is the purpose of the ENERGY 3 study?

The study aims to find out if the medicine INZ-701 is safe and effective at balancing minerals and improving bone growth in children.

כמה זמן נמשך המחקר?

The main part of the study runs for 52 weeks (approximately one year) of treatment and regular monitoring.

Will taking part cost anything?

No, the study medicine and all related tests are provided free of charge. Travel expenses to study visits are usually reimbursed.

Can my child leave the study if we change our mind?

Yes, you can choose to stop participating at any time. Your child's normal medical care will continue as usual.

כיצד לגלות עוד

תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.

מעוניינים להשתתף?

רשום את התעניינותך

שתף את הפרטים שלך וצוות המחקר עבור "The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Ph…" ייצרו איתך קשר אם אתה עשוי להיות זכאי. תמיד התייעץ עם הרופא שלך לפני שאתה מסכים להשתתף.

דיון

דיון קהילתי

מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.